219 related articles for article (PubMed ID: 15025416)
1. Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.
de Boer MG; Kroon FP; Kauffmann RH; Vriesendorp R; Zwinderman K; van Dissel JT
Neth J Med; 2003 Dec; 61(12):408-12. PubMed ID: 15025416
[TBL] [Abstract][Full Text] [Related]
2. Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.
Tangsinmankong N; Kamchaisatian W; Lujan-Zilbermann J; Brown CL; Sleasman JW; Emmanuel PJ
J Allergy Clin Immunol; 2004 Apr; 113(4):742-6. PubMed ID: 15100682
[TBL] [Abstract][Full Text] [Related]
3. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
4. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
Phillips P; Bonner S; Gataric N; Bai T; Wilcox P; Hogg R; O'Shaughnessy M; Montaner J
Clin Infect Dis; 2005 Nov; 41(10):1483-97. PubMed ID: 16231262
[TBL] [Abstract][Full Text] [Related]
5. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
6. Change in T-lymphocyte count after initiation of highly active antiretroviral therapy in HIV-infected patients with history of Mycobacterium avium complex infection.
Lazaro E; Coureau G; Guedj J; Blanco P; Pellegrin I; Commenges D; Dabis F; Moreau JF; Pellegrin JL; Thiébaut R;
Antivir Ther; 2006; 11(3):343-50. PubMed ID: 16759051
[TBL] [Abstract][Full Text] [Related]
7. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
8. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
9. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy.
Keane NM; Price P; Lee S; Almeida CA; Stone SF; James I; French MA
HIV Med; 2004 Nov; 5(6):407-14. PubMed ID: 15544692
[TBL] [Abstract][Full Text] [Related]
10. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis.
Tan DB; Yong YK; Tan HY; Kamarulzaman A; Tan LH; Lim A; James I; French M; Price P
HIV Med; 2008 May; 9(5):307-16. PubMed ID: 18400078
[TBL] [Abstract][Full Text] [Related]
11. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
Bonnet F; Thiébaut R; Chêne G; Neau D; Pellegrin JL; Mercié P; Beylot J; Dabis F; Salamon R; Morlat P;
HIV Med; 2005 May; 6(3):198-205. PubMed ID: 15876287
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
13. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of asymptomatic HIV-infected patients who discontinued antiretroviral therapy.
Fernández Guerrero ML; Rivas P; Molina M; Garcia R; De Górgolas M
Clin Infect Dis; 2005 Aug; 41(3):390-4. PubMed ID: 16007538
[TBL] [Abstract][Full Text] [Related]
16. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
18. Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.
Mussini C; Manzardo C; Johnson M; Monforte Ad; Uberti-Foppa C; Antinori A; Gill MJ; Sighinolfi L; Borghi V; Lazzarin A; Miró JM; Sabin C;
AIDS; 2008 Nov; 22(18):2461-9. PubMed ID: 19005269
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility to opportunistic infections in HIV-infected patients with increased CD4 T-cell counts on antiretroviral therapy may be predicted by markers of dysfunctional effector memory CD4 T cells and B cells.
French M; Keane N; McKinnon E; Phung S; Price P
HIV Med; 2007 Apr; 8(3):148-55. PubMed ID: 17461858
[TBL] [Abstract][Full Text] [Related]
20. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]